Reilly Financial Advisors LLC raised its position in Celgene Corporation (NASDAQ:CELG) by 52.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,846 shares of the biopharmaceutical company’s stock after buying an additional 635 shares during the period. Reilly Financial Advisors LLC’s holdings in Celgene Corporation were worth $240,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the company. Swiss National Bank raised its position in Celgene Corporation by 27.2% in the first quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock worth $341,796,000 after buying an additional 588,000 shares in the last quarter. Edge Wealth Management LLC raised its position in Celgene Corporation by 10.5% in the first quarter. Edge Wealth Management LLC now owns 15,920 shares of the biopharmaceutical company’s stock worth $1,979,000 after buying an additional 1,518 shares in the last quarter. Boston Partners raised its position in Celgene Corporation by 0.3% in the first quarter. Boston Partners now owns 197,861 shares of the biopharmaceutical company’s stock worth $24,620,000 after buying an additional 541 shares in the last quarter. Catawba Capital Management VA raised its position in Celgene Corporation by 12.0% in the first quarter. Catawba Capital Management VA now owns 2,425 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 260 shares in the last quarter. Finally, Train Babcock Advisors LLC acquired a new position in Celgene Corporation during the first quarter worth approximately $205,000. 78.41% of the stock is currently owned by institutional investors.

Shares of Celgene Corporation (CELG) traded up 0.11% during midday trading on Monday, hitting $136.85. The company’s stock had a trading volume of 1,144,190 shares. The company has a 50-day moving average price of $132.00 and a 200 day moving average price of $123.32. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $139.00. The company has a market cap of $107.06 billion, a P/E ratio of 42.38 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.21. The company had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm’s revenue was up 18.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.44 EPS. On average, equities research analysts predict that Celgene Corporation will post $7.32 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/08/07/celgene-corporation-nasdaqcelg-stake-raised-by-reilly-financial-advisors-llc.html.

A number of equities analysts have commented on CELG shares. BTIG Research reissued a “buy” rating and issued a $138.00 price objective on shares of Celgene Corporation in a research note on Wednesday, May 24th. Argus raised Celgene Corporation from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $96.93 to $160.00 in a research note on Monday, July 31st. Jefferies Group LLC reissued a “buy” rating and issued a $160.00 price objective on shares of Celgene Corporation in a research note on Tuesday, July 11th. Zacks Investment Research lowered Celgene Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Finally, Cantor Fitzgerald set a $160.00 price objective on Celgene Corporation and gave the stock a “buy” rating in a research note on Thursday, July 6th. One analyst has rated the stock with a sell rating, six have given a hold rating and twenty-three have assigned a buy rating to the company. Celgene Corporation presently has a consensus rating of “Buy” and an average price target of $147.06.

In other news, Director Michael D. Casey sold 9,250 shares of the business’s stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $125.59, for a total value of $1,161,707.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Rupert Vessey sold 4,785 shares of the business’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the transaction, the insider now directly owns 4,004 shares in the company, valued at $481,200.72. The disclosure for this sale can be found here. Insiders sold a total of 235,255 shares of company stock worth $31,377,042 over the last three months. 0.95% of the stock is owned by company insiders.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.